Valsartan vs. Lisinopril: Key Differences to Know

Valsartan and lisinopril lower blood pressure about equally well, but they belong to different drug classes and diverge sharply in side effects, tolerability, and how they perform in specific clinical situations like heart failure and kidney disease. Lisinopril is an ACE inhibitor, one of the most widely prescribed medications in the world, while valsartan is an angiotensin receptor blocker (ARB). That distinction in mechanism sounds academic, but it drives real differences in who tolerates which drug, who sticks with treatment, and when one might be chosen over the other.

How Each Drug Works

Both valsartan and lisinopril target the same hormonal system, called the renin-angiotensin-aldosterone system, which regulates blood pressure and fluid balance. Lisinopril blocks the enzyme that converts angiotensin I into angiotensin II, a hormone that constricts blood vessels. By preventing that conversion, lisinopril keeps blood vessels relaxed and blood pressure lower. But that same enzyme also breaks down a substance called bradykinin. When the enzyme is blocked, bradykinin accumulates, and that buildup is responsible for the persistent dry cough that plagues many people on ACE inhibitors.

Valsartan takes a different approach. Instead of blocking the enzyme, it blocks the receptor where angiotensin II docks on blood vessel walls. The hormone still gets made, but it can’t do its job. Because valsartan doesn’t interfere with bradykinin breakdown, the cough problem is largely avoided. This single mechanistic difference accounts for the biggest practical gap between the two drugs.

Blood Pressure Lowering Is Essentially a Tie

Multiple head-to-head trials have compared valsartan and lisinopril directly, and the results are consistent: both drugs bring blood pressure down by about the same amount. In the PREVAIL study, which tested valsartan 160 mg against lisinopril 20 mg (with the option to add a diuretic), average blood pressure dropped by about 31/16 mmHg in both groups, and blood pressure was controlled in roughly 82% of patients on valsartan and 82% on lisinopril.¹

A trial focused specifically on older adults found a similarly tight match. About 80% of patients responded to treatment in both groups after 12 weeks, rising to 81% for valsartan and 87% for lisinopril at one year, with no statistically significant difference.² A third trial using titrated doses confirmed the pattern, finding no significant difference between active treatment groups in blood pressure reduction.³ If your only concern is whether one pill pushes blood pressure numbers down further than the other, the answer is that they’re interchangeable.

The Cough That Drives People Away From ACE Inhibitors

The most talked-about difference between these two drugs is cough. ACE inhibitor cough is dry, persistent, and annoying enough that it drives a substantial number of patients to stop their medication. In a study specifically designed to compare cough rates, nearly 69% of patients with a history of ACE inhibitor cough experienced cough on lisinopril, compared to about 20% on valsartan, a rate that was statistically indistinguishable from placebo.⁴ That study enrolled people already known to be cough-prone on ACE inhibitors, so the lisinopril cough rate was higher than you’d see in the general population. But even in unselected patients, ACE inhibitor cough affects roughly 5 to 20% of people, with higher rates in women and in people of East Asian descent.

Closely related to the cough issue is angioedema, a rarer but more dangerous allergic-type reaction that causes swelling of the lips, tongue, throat, or face. ACE inhibitors carry a recognized risk of angioedema, again driven by bradykinin accumulation. ARBs like valsartan show an incidence of angioedema comparable to placebo.⁵ For anyone who has experienced angioedema on lisinopril, switching to valsartan is a standard clinical move, though careful monitoring is still recommended because rare crossover reactions have been reported.

Who Sticks With Treatment Longer

A blood pressure medication only works if you take it, and tolerability matters more than most people realize. A large observational study comparing persistence across common blood pressure drugs found that valsartan users were significantly more likely to stay on their medication than lisinopril users. The risk of discontinuation was about 14% higher for lisinopril compared to valsartan.⁶ That gap may seem modest, but over years of treatment, it translates into a meaningful number of people whose blood pressure creeps back up because they abandoned their pill. Side effects, particularly cough, are a major reason ACE inhibitor adherence suffers.

Cost also factors in. Lisinopril has been generic for decades and is one of the cheapest blood pressure medications available, sometimes costing just a few dollars a month. Valsartan went generic more recently and is still slightly more expensive at many pharmacies, though the gap has narrowed considerably. For patients without insurance coverage, the price difference can influence which drug gets prescribed first.

After a Heart Attack

Both drugs are used to protect the heart after a heart attack, particularly when there’s evidence of reduced heart function. The VALIANT trial, one of the largest post-heart attack studies ever conducted, enrolled over 14,000 patients and compared valsartan, the ACE inhibitor captopril, and the two drugs together. During a median follow-up of about two years, mortality was virtually identical across all three groups, and valsartan met the statistical threshold for noninferiority compared to captopril.⁷ Follow-up imaging confirmed that all three treatment strategies produced similar improvements in heart size and pumping function over 20 months.⁸

Combining an ACE inhibitor with an ARB after a heart attack did not improve outcomes beyond using either one alone, and the combination arm had more side effects. That finding helped settle a debate about whether dual blockade of the renin-angiotensin system might offer additive benefit. For most post-heart attack patients, guidelines now recommend either an ACE inhibitor or an ARB, not both.⁹

Heart Failure and the Sacubitril-Valsartan Combination

In heart failure, ACE inhibitors like lisinopril have been a cornerstone of therapy for decades, based on strong evidence that they reduce hospitalization and death. Valsartan alone performs comparably: a head-to-head trial in chronic heart failure found no significant differences between valsartan and lisinopril in their effects on heart function, blood pressure, or aldosterone levels.¹⁰

Where valsartan has gained a distinct edge in heart failure is through its combination with sacubitril, sold as Entresto. The PARADIGM-HF trial showed that sacubitril-valsartan was superior to the ACE inhibitor enalapril in reducing the combined risk of cardiovascular death and heart failure hospitalization, with a roughly 20% reduction in cardiovascular death and improved overall survival.¹¹ A meta-analysis of randomized trials confirmed these findings, showing that sacubitril-valsartan reduced heart failure hospitalizations by about 20%, cardiovascular mortality by about 14%, and all-cause mortality by about 11% compared to ACE inhibitors or ARBs alone.¹²

Real-world data from a large matched-pair study found that sacubitril-valsartan was associated with about a 20% reduction in all-cause mortality and a 14% reduction in all-cause hospitalization compared to standard ACE inhibitor or ARB therapy.¹³ This combination has shifted clinical practice substantially. For patients with heart failure and a reduced ejection fraction, sacubitril-valsartan has replaced ACE inhibitors as the preferred agent in many guidelines. If you’re on lisinopril for heart failure, your doctor may eventually discuss switching to sacubitril-valsartan, though the switch needs to include a short washout period to reduce the risk of angioedema.

Protecting the Kidneys in Diabetes

Both ACE inhibitors and ARBs are recommended for people with diabetes who have early signs of kidney damage, because blocking the renin-angiotensin system reduces the pressure inside kidney filters and slows the progression of protein leaking into the urine. Valsartan has specific evidence here: in the Microalbuminuria Reduction with Valsartan study, valsartan reduced albumin in the urine by 44%, compared to just 8% with the blood pressure drug amlodipine, and restored normal urinary albumin levels in 30% of patients versus 15% with amlodipine.¹⁴

When researchers compared different ARBs head to head for kidney protection in diabetic patients with protein in their urine, valsartan performed at least as well as other ARBs. Irbesartan was actually associated with a higher rate of the primary kidney outcome compared to valsartan, though no significant differences were seen in death or dangerously high potassium levels among the ARBs tested.¹⁵ Whether ACE inhibitors or ARBs offer better kidney protection overall remains an open question. Major guidelines treat both classes as roughly equivalent for this purpose, choosing between them based on tolerability.

Potassium Levels and Kidney Function

Both valsartan and lisinopril can raise potassium levels, and this shared risk is one reason neither drug should be combined with the other (a lesson reinforced by the VALIANT and similar trials). The clinical concern is highest in people with reduced kidney function, diabetes, or those already taking other medications that raise potassium.

One comparative study found that ARB users had a 42 to 56% higher odds of developing elevated potassium compared to ACE inhibitor users, depending on how kidney function was measured.¹⁶ However, a study comparing lisinopril and valsartan directly in people with impaired kidneys found the opposite pattern for the lower-GFR subgroup: lisinopril raised potassium by an average of 0.28 mEq/L, while valsartan raised it by only 0.12 mEq/L, about 43% less. That smaller bump with valsartan was accompanied by less aldosterone suppression, suggesting a subtly different hormonal response.¹⁷

The evidence is mixed enough that neither drug gets a clean win on potassium safety. The practical takeaway is that if you have significant kidney disease, your doctor will monitor your potassium and kidney function regardless of which drug you’re taking, and the choice between valsartan and lisinopril will likely hinge on other factors like cough tolerance.

Pregnancy and Fertility

Both valsartan and lisinopril are absolutely contraindicated in pregnancy. Exposure to either drug during the second and third trimesters can cause serious harm to the developing fetus, including kidney failure, low amniotic fluid, underdeveloped skulls, lung problems, and even fetal death. A systematic review of pregnancy outcomes found that neonatal complications were more frequent following ARB exposure than ACE inhibitor exposure, with positive long-term outcomes described in only about half of exposed children.¹⁸ Case reports have documented similar patterns of fetal kidney injury from ARB exposure during the second half of pregnancy.¹⁹

If you’re planning a pregnancy or discover you’re pregnant while taking either drug, the standard guidance is to stop immediately and switch to a blood pressure medication considered safer in pregnancy, such as labetalol, nifedipine, or methyldopa. This applies equally to valsartan and lisinopril, with no advantage to either one in this context.

Interactions With Pain Relievers

Nonsteroidal anti-inflammatory drugs like ibuprofen and naproxen can blunt the blood-pressure-lowering effect of both valsartan and lisinopril.²⁰ A trial testing the effect of the prescription NSAID indomethacin on both drugs found that blood pressure crept up in both groups when the NSAID was added. The rise was numerically larger with lisinopril (about 5/3 mmHg) than with valsartan (about 2/2 mmHg), though the difference between the two drugs did not reach statistical significance.²¹ The practical message is the same for both: if you regularly take over-the-counter anti-inflammatory painkillers, tell your doctor, because it can undermine your blood pressure control and increase the risk of kidney problems.

Racial and Ethnic Differences in Response

ACE inhibitors as a class tend to produce smaller blood pressure reductions in Black patients compared to non-Black patients. The ALLHAT trial, one of the largest hypertension trials ever run, showed that Black patients randomized to lisinopril had meaningfully higher blood pressures during follow-up than those randomized to the diuretic chlorthalidone, with a gap of about 4-5 mmHg systolic that persisted over years. Among non-Black patients, the difference between lisinopril and chlorthalidone was less than 1 mmHg.²²

ARBs like valsartan also show somewhat reduced blood pressure lowering in Black patients, though the gap tends to be smaller than with ACE inhibitors. For this reason, current guidelines generally recommend that Black patients without kidney disease or heart failure start with either a calcium channel blocker or a thiazide diuretic rather than an ACE inhibitor or ARB. When an ACE inhibitor or ARB is needed, as it often is for people with diabetes or chronic kidney disease regardless of race, either drug remains appropriate.

The Valsartan Recall and What It Meant

In 2018, several generic versions of valsartan were pulled from shelves worldwide after a contaminant called NDMA, a probable carcinogen, was discovered in products manufactured by certain companies. The recalls affected valsartan specifically (along with some other ARBs like losartan and irbesartan) and caused understandable alarm among patients.²³ The contamination was traced to changes in manufacturing processes at specific facilities, not to any inherent problem with valsartan as a molecule. Regulatory agencies responded with tighter testing requirements, and valsartan products currently on the market have been cleared of contamination concerns. Still, the episode shook patient confidence and prompted some people to switch to lisinopril or other blood pressure medications. If you were affected by the recall, it’s worth knowing that the issue has been resolved through manufacturing and regulatory changes, not by abandoning the drug.

When Timing Matters

You may have heard advice about taking blood pressure medication at bedtime instead of in the morning. The idea is that nighttime dosing might better protect against the early-morning blood pressure surge linked to heart attacks and strokes. However, a review of the evidence found no convincing proof that evening dosing of blood pressure drugs provides a significant advantage in blood pressure control, organ damage prevention, or cardiovascular event reduction compared to morning dosing.²⁴ This applies equally to both valsartan and lisinopril. The most important thing is taking either drug consistently at the same time every day.

One practical difference: lisinopril is taken once daily, and valsartan is also usually once daily at the higher doses used for hypertension, though some patients on lower doses or those being treated for heart failure may take it twice daily. Valsartan has a somewhat shorter duration of action, and its bioavailability is relatively low, with only about 7-13% of an oral dose reaching the bloodstream as active drug.²⁵ Despite that low absorption, the clinical effect is robust because the drug binds tightly to its target receptor. Lisinopril, by contrast, does not undergo liver metabolism and is excreted unchanged by the kidneys, which means kidney function affects how much drug accumulates in the body and whether doses need adjustment.